公开(公告)号：US10138303B2

公开(公告)日：2018-11-27

申请号：US15351275

申请日：2016-11-14

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Weihsien Ho ,  Jaume Pons ,  Arvind Rajpal ,  Pavel Strop

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.

公开(公告)号：US10155037B2

公开(公告)日：2018-12-18

申请号：US14958053

申请日：2015-12-03

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Weihsien Ho ,  Arvind Rajpal ,  Sawsan Youssef

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US10660953B2

公开(公告)日：2020-05-26

申请号：US16188120

申请日：2018-11-12

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Weihsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.